Medmix - Public Comps and Valuation Multiples

Medmix Overview

About Medmix

Medmix AG delivers technologies in high-precision delivery devices and fluid mixing for applications. It is into two business areas Healthcare and Consumer & Industrial. The Healthcare business area is divided into the Dental, Drug Delivery, and Surgery segments. The Consumer & Industrial business area operates through the Industry and Beauty segments. The majority of its revenue is from the Consumer & Industrial segment. In the Industry segment, dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways, and aerospace), electronics assembly, infrastructure, and DIY industries. Geographically, it operates in Europe the Middle East and Africa, the Americas, and Asia-Pacific.

Founded

2021

HQ

Employees

2.7K+

Website

medmix.swiss

Sectors

Medical Devices
Industrial Parts
DeepTech
HealthTech

Financials

LTM Revenue $570M

LTM EBITDA $107M

EV

$733M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Medmix Financials

As of September 2025, Medmix reported last 12-month revenue of $570M and EBITDA of $107M.

In the same period, Medmix generated $167M in LTM gross profit and $7.0M in net income.

See Medmix valuation multiples based on analyst estimates

Medmix P&L

In the most recent fiscal year, Medmix reported revenue of $602M and EBITDA of $83.7M.

Medmix expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Medmix valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$570M	XXX	$602M	XXX	XXX	XXX
Gross Profit	$167M	XXX	$199M	XXX	XXX	XXX
Gross Margin	29%	XXX	33%	XXX	XXX	XXX
EBITDA	$107M	XXX	$83.7M	XXX	XXX	XXX
EBITDA Margin	19%	XXX	14%	XXX	XXX	XXX
EBIT	$29.0M	XXX	$22.5M	XXX	XXX	XXX
EBIT Margin	5%	XXX	4%	XXX	XXX	XXX
Net Profit	$7.0M	XXX	-$9.2M	XXX	XXX	XXX
Net Margin	1%	XXX	-2%	XXX	XXX	XXX
Net Debt	XXX	XXX	$202M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Medmix including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $570M. EBITDA for the last twelve months was $107M. In the most recent fiscal year, Medmix achieved $602M in revenue and $83.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$570M	Analyst estimates available to subscribers	$602M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$167M	Analyst estimates available to subscribers	$199M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	29.3% gross margin	Analyst estimates available to subscribers	33.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$107M	Analyst estimates available to subscribers	$83.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	18.8% EBITDA margin	Analyst estimates available to subscribers	13.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$29.0M	Analyst estimates available to subscribers	$22.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	5.1% EBIT margin	Analyst estimates available to subscribers	3.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$7.0M	Analyst estimates available to subscribers	-$9.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	1.2% net profit margin	Analyst estimates available to subscribers	-1.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$202M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Medmix

This financial data table provides comprehensive performance metrics for Medmix, a company based in Switzerland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Medmix generated $570M in revenue over the last twelve months.
The company achieved $107M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $167M.
Net income over the last twelve months reached $7.0M.

Fiscal Year Performance

In the most recent fiscal year, Medmix reported $602M in total revenue.
Fiscal year EBITDA was $83.7M.
The company maintained a gross profit margin of 33.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 13.9%.
Net profit margin reached -1.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Medmix. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Medmix Stock Performance

Medmix has current market cap of CHF 377M (or $469M), and EV of CHF 589M (or $733M).

Market Cap Evolution

Medmix Stock Data

As of October 17, 2025, Medmix's stock price is CHF 9 (or $11).

See Medmix trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$733M	$469M	XXX	XXX	XXX	XXX	$0.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Medmix Valuation Multiples

Medmix's trades at 1.2x EV/Revenue multiple, and 8.8x EV/EBITDA.

See valuation multiples for Medmix and 15K+ public comps

Medmix Financial Valuation Multiples

As of October 17, 2025, Medmix has market cap of $469M and EV of $733M.

Equity research analysts estimate Medmix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medmix has a P/E ratio of 66.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$469M	XXX	$469M	XXX	XXX	XXX
EV (current)	$733M	XXX	$733M	XXX	XXX	XXX
EV/Revenue	1.3x	XXX	1.2x	XXX	XXX	XXX
EV/EBITDA	6.8x	XXX	8.8x	XXX	XXX	XXX
EV/EBIT	25.3x	XXX	32.6x	XXX	XXX	XXX
EV/Gross Profit	4.4x	XXX	n/a	XXX	XXX	XXX
P/E	66.6x	XXX	-51.0x	XXX	XXX	XXX
EV/FCF	29.0x	XXX	15.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Medmix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Medmix Margins & Growth Rates

Medmix's last 12 month revenue growth is 2%

Medmix's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Medmix's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medmix's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Medmix and other 15K+ public comps

Medmix Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	2%	XXX	-1%	XXX	XXX	XXX
EBITDA Margin	19%	XXX	14%	XXX	XXX	XXX
EBITDA Growth	8%	XXX	10%	XXX	XXX	XXX
Rule of 40	17%	XXX	16%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	25%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	29%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial